J.M. Smucker/$SJM

1D1W1MYTD1Y5YMAX

About J.M. Smucker

J.M. Smucker is a packaged food company that primarily sells through the US retail channel (75% of fiscal 2026 revenue came through its retail pet foods, coffee, and frozen handheld/spreads segments), with the remaining share consisting of sweet baked snacks (through the Hostess acquisition), away from home, and international (primarily Canada). Retail coffee is its largest category (37% of sales) with brands Folgers, Dunkin', and Cafe Bustelo. Pet foods (18% of sales) holds leading brands like Milk-Bone and Meow Mix. Of its remaining, approximately 20% comes from frozen handhelds and spreads, through brands Jif, Smucker's, and Uncrustables. The company acquired Hostess Brands in fiscal 2024 to boost its snack and convenience store presence.
Ticker
$SJM
Primary listing
NYSE
Employees
8,000

J.M. Smucker Metrics

BasicAdvanced
$13B
56.65
$2.15
0.25
$4.42
3.68%

What the Analysts think about J.M. Smucker

Analyst ratings (Buy, Hold, Sell) for J.M. Smucker stock.
Analyst projections of the future price of J.M. Smucker stock.

Bulls say / Bears say

Easing green coffee costs are expected to boost margin expansion and support adjusted EPS guidance of $9.75–$10.25 for fiscal 2027, above consensus forecasts (Reuters)
Resilient demand for Uncrustables sandwiches and Hostess donuts, part of the Hostess acquisition, is driving diversification and sent shares up 12% on the earnings release date (Reuters)
The board approved a quarterly dividend of $1.10 per share payable June 1, 2026—marking 56 consecutive years of dividend payments and yielding approximately 4.7%—underscoring strong shareholder return commitment (Reuters)
Full-year fiscal 2027 guidance calls for net sales to decline 3.0%–4.0%, signaling anticipated top-line contraction across key product categories (SEC 8-K)
CEO Mark Smucker warned that green coffee deflation will be a headwind to net sales, implying margin gains may come at the expense of revenue volume (Reuters)
Smucker notes consumers are shifting toward cheaper private labels and healthier options—accelerated by GLP-1 weight-loss drug adoption—which underpins the company’s downward sales guidance (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 26 Aug 2026.

J.M. Smucker Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

J.M. Smucker Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

Funds containing J.M. Smucker

AllEURGBPUSD
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.